Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359933 | 0.89 | DHFR (0.65) | DHFR | |
| SCHEMBL5359927 | 0.88 | ALDH1A1 (0.61) | DHFR | |
| SCHEMBL5355383 | 0.83 | DHFR (0.60) | DHFR | |
| SCHEMBL28119906 | 0.82 | MAP4K4 (0.66) | DHFRLTA4H | |
| SCHEMBL5356890 | 0.81 | DHFR (0.70) | DHFRAPPSLC2A1 | |
| SCHEMBL5358700 | 0.81 | DHFR (0.67) | DHFR | |
| SCHEMBL5348919 | 0.79 | KDM4E (0.58) | DHFR | |
| SCHEMBL5355655 | 0.79 | DHFR (0.67) | DHFRSLC2A1 | |
| SCHEMBL5363232 | 0.78 | DHFR (0.56) | DHFR | |
| SCHEMBL29415515 | 0.75 | LTA4H (0.49) | DHFRLTA4HLTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256197-B2 | Methods for synthesis of diarylmethanes | DANA-FARBER CANCER INSTITUTE (US) | 2007-08-14 | — | — | US | disclosed |
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DANA-FARBER CANCER INSTITUTE | 2004-12-30 | — | — | US | disclosed |
| WO-2003031458-A1 | METHODS FOR SYNTHESIS OF DIARYLMETHANES | DANA-FARBER CANCER INSTITUTE (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DHFR, DPYD, DHODH | DHFR 1/4885APP 4586/4885SLC2A1 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.